Genetically engineered bacteria offer new hope for pancreatic cancer treatment

Tuesday 28 July 2026 - 18:18

By: Azzat Manal

Genetically engineered bacteria offer new hope for pancreatic cancer treatment

Researchers at the University of Chicago have developed a promising experimental approach that could open new avenues in the fight against pancreatic cancer, one of the most difficult cancers to treat with conventional immunotherapy.

The strategy uses a genetically modified probiotic bacterium called BifidoSumIL-2, designed to deliver an immune-stimulating treatment directly into tumors. The approach aims to overcome one of the main challenges associated with pancreatic cancer: the tumor's ability to create an immunologically "cold" environment that prevents immune cells from effectively attacking cancerous tissue.

In experiments conducted on animal models, the treatment helped slow tumor growth by selectively activating cancer-fighting T cells. Researchers found that this response could also modify the environment surrounding the tumor, potentially making it more receptive to additional treatments.

The experimental therapy is based on Bifidobacterium longum, a probiotic bacterium naturally found in the human digestive system. Scientists genetically modified the microorganism to act as a targeted drug delivery system. Because it can thrive in oxygen-poor environments, a characteristic commonly found inside solid tumors, the bacterium may be able to reach cancerous tissue while being naturally eliminated from healthy, oxygen-rich areas.

The modified bacteria carry a specially engineered version of interleukin-2, known as SumIL-2. This immune molecule is designed to stimulate T cells involved in fighting cancer while limiting the activation of other immune cells that could weaken the body's antitumor response. Researchers hope this targeted mechanism could reduce some of the limitations associated with earlier forms of immunotherapy.

According to findings published in Science Advances, the experimental treatment appeared to become even more effective when combined with established cancer therapies. In animal studies, combining BifidoSumIL-2 with chemotherapy, radiation therapy or PD-L1 immunotherapy improved tumor control and survival compared with individual treatments used alone.

The research reflects a broader scientific effort to explore the concept of "bacteria as medicine," in which modified microorganisms are developed to deliver therapeutic substances directly to difficult-to-reach tumors. Such approaches could eventually contribute to more precise cancer treatments while potentially limiting damage to healthy tissues.

However, the researchers emphasize that the treatment remains at the experimental stage and has not yet been tested in humans. Further studies will be required to assess its long-term safety, determine the most effective method of administration and evaluate the durability of the immune response. Scientists will also need to investigate whether the approach can be successfully combined with emerging therapies, including treatments targeting KRAS mutations.

The development of BifidoSumIL-2 highlights the growing intersection between microbiology, immunology and oncology. While significant research remains before the approach could be considered for clinical use, the findings offer a potential new direction in the search for more effective treatments for pancreatic cancer.